German Auto Suppliers Turn Bearish as Investment and Jobs Shift Overseas 
SoftBank Vision Fund CFO Navneet Govil to Exit After Decade-Long Tenure 
Asian Markets Mixed Ahead of Key Central Bank Decisions 
Dollar Slips as U.S.-Iran Peace Deal Boosts Risk Appetite and Pressures Safe-Haven Demand 
RBA Expected to Hold Interest Rates at 4.35% as Markets Watch AUD/USD and ASX 200 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Wall Street Surges as US-Iran Deal Eases Oil Price and Inflation Concerns 
Anthropic Officials Meet White House Over AI Model Outage 
North Korea Reports Industrial Output at 105% of Target Following Party Congress 
Anthropic Restricts Global Access to AI Models After U.S. Security Review 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Woodside Energy Denies Exxon Mobil Takeover Talks Amid LNG Growth Focus 
BOJ Raises Interest Rates to 1% as Inflation Pressures Persist 
BOJ Raises Interest Rates to 31-Year High, Signals Strong Focus on Inflation Risks 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Pfizer announced on Wednesday, April 28, that it has acquired Amplyx Pharmaceuticals. The company stated that the purchase would bolster its portfolio as it offers the opportunity to strengthen “Pfizer’s expertise and deep heritage in infectious disease.”
As per Reuters, Amplyx Pharmaceuticals is based in San Diego, and it is developing new treatments against drug-resistant microbes in patients with compromised immune systems.
The anti-fungal drug has been named fosmanogepix, and it is now in the second phase of clinical trials.
Pfizer to continue testing on Amplyx’s experimental drug
The New York-headquartered multinational pharmaceutical company acquired Amplyx while it is in the middle of conducting trials for its anti-fungal drug that is hoped to effectively fight off drug-resistant infections that ravage the immune system of patients. Since this is the case, Pfizer will not abandon but continue the clinical trials of this experimental drug.
If Amplyx's fosmanogepix drug will show good results and eventually be approved, it will become the first type of new antifungal treatment to come in the last 20 years. This is an important drug because it can kill fungi, like bacteria, that have turned resistant to common drugs or medicines.
Why Pfizer is further expanding its infectious disease folio
It was estimated that if this kind of drug will not be developed, drug-resistant superbugs may possibly kill at least 10 million people by 2050. This is why Pfizer has been expanding its portfolio for treatments that can fight these threatening superbugs.
Pfizer noted that hospitalized patients’ immune systems tend to become weaker since the drugs they take do not work, and this has become a problem not just for the ill but for doctors as well. This scenario just showed how much people need effective anti-fungal treatments for such patients.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” Pfizer Hospital’s global president, Angela Lukin, said in a press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies.”
